Insights center
Insights
Read dated, source-based notes that separate China healthcare policy context from product-specific decisions and advisory services.
Policy notes
Current context, official sources, and questions to test.
These articles are general information. Each keeps its source links, review date, pathway limits, and product-specific questions separate from service descriptions.
-
national registration · medical devices · drugs
National registration and filing — a planning baseline for imported products
A general introduction to the formal NMPA route for imported drugs and medical devices, with classification and evidence questions kept visible.
Last reviewed: 2 August 2026
Read the source-based note -
Hainan Free Trade Port · customs framework · current status
Hainan Free Trade Port special customs operations — current status and limits
A current-status note separating Hainan’s island-wide special customs framework from product-specific healthcare access and regulatory permissions.
Last reviewed: 2 August 2026
Read the source-based note -
Greater Bay Area · urgent clinical use · designated institutions
Greater Bay Area urgent clinical use — scope, institutions, and limits
A dated overview of Guangdong’s measure for eligible Hong Kong drugs and medical devices at designated institutions in nine mainland cities.
Last reviewed: 2 August 2026
Read the source-based note -
Boao Lecheng · special access · real-world evidence
Boao Lecheng special access — questions before considering fit
A source-based overview of the institution-led route for selected clinically needed imported drugs and medical devices in Boao Lecheng.
Last reviewed: 2 August 2026
Read the source-based note